Monthly Archives: May 2020

Bergio International Implementing A New Direction

Launches New Channel Direct to Consumers

FAIRFIELD, NJ / ACCESSWIRE / May 27, 2020 / Bergio International, Inc. ("Bergio", or the "Company") (OTC PINK:BRGO), a leading designer, manufacturer and retail outlet for the Bergio Brand of designer jewelry, including exquisite collections of rings, necklaces, earrings, and other fine accessories, today reported that it is implementing a new direction to improve revenues. Bergio will be launching its own live channel direct to consumer to be broadcasted live 3 times a week from its store location in the Ocean Casino Resort in Atlantic City NJ. The launch date will be predicated on opening of the casino. We anticipate being up and live within 30 days unless there are additional delays from the State.

Berge Abajian, CEO of Bergio stated "the introduction of our online live broadcast is a great addition to our existing business. We have succeeded in transforming our business the past 5 years from strictly wholesale to selling direct to consumer. This platform provides us the opportunity to penetrate the worldwide market. My vision and direction, which was painful to execute, has moved us in the right direction. Our gross margins have increased tremendously and are operating expenses are under control, providing for a highly leveraged company. We believe that revenues will increase as a result of this new strategy and provide improved profitability in the future. While jewelry market has experienced a modest downturn which has caused a decline in our revenues, this new platform should allow and provide more worldwide market penetration. Bergio is ready for the future as we have worked hard on our product mix and added accessories & Silver Fashion Jewelry in 2019 with a great price point that gives our consumer base a large selection to pick from."

I appreciate all the support from our shareholders and wishing all to stay safe through this tough times, knowing that a bright future is ahead."
For further information please visit our website at www.bergio.com.

# # #

This press release includes statements that are not historical in nature and may be characterized as "forward-looking statements," including those related to future financial and operating results, benefits, and synergies of the combined companies, statements concerning the Company's outlook, pricing trends, and forces within the industry, the completion dates of capital projects, expected sales growth, cost reduction strategies, and their results, long-term goals of the Company and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends, and similar expressions concerning matters that are not historical facts. All predictions as to future results contain a measure of uncertainty and, accordingly, actual results could differ materially. Among the factors which could cause a difference are: changes in the general economy; changes in demand for the Company's products or in the cost and availability of its raw materials; the actions of its competitors; the success of our customers; technological change; changes in employee relations; government regulations; litigation, including its inherent uncertainty; difficulties in plant operations and materials; transportation, environmental matters; and other unforeseen circumstances. A number of these factors are discussed in the Company's previous filings with the U.S. Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 (the "Act") protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact: Berge Abajian
Bergio International, Inc.
(973) 227-3230
berge@bergio.com

SOURCE: Bergio International, Inc.

ReleaseID: 591420

AQUALUNG THERAPEUTICS CORP. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS and the Critically Ill

New Hope for Treating Major Cause of COVID-19 Deaths

Even before the COVID-19 Pandemic, each year 500,000 patients in the US, 2 million patients globally, develop ARDS due to bacterial and viral causes of pneumonia, trauma and other infections

TUCSON, AZ / ACCESSWIRE / May 27, 2020 / In June 2019, Aqualung Therapeutics received a three year $1.7M dollar NIH Fastrack Award, for development of a novel immune-based anti-inflammatory therapeutic antibody for critically ill patients with acute lung injury. Due to progress in completion of the initial Fastrack Phase I studies, the company has received National Heart Lung & Blood Institute approval for Fastrack Phase II Funding. Aqualung has now begun IND-enabling pharmaco-dynamic, pharmacokinetic and toxicology studies that will advance their lead therapeutic ALT-100 into human studies to treat Acute Respiratory Distress Syndrome (ARDS). ALT-100 is a humanized monoclonal antibody designed to neutralize circulating extracellular NAMPT, as a novel biologic to suppress lung and systemic inflammatory cascades, inclusive of Covid-19-induced ARDS.

To view the full announcement, including visuals, bios, downloadable resources, and more, click here.

Key Takeaways

Many COVID-19 deaths begin with SARS-CoV2 virus-induced pneumonia which has dramatically increased the number of ARDS cases worldwide.
ARDS patients in the US have a very high 30-40% mortality rate, higher in other parts of the world.
There are no FDA-approved drugs for ARDS.

About Aqualung Therapeutics Corporation

Aqualung is an early stage biotech company developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung and systemic inflammation. Founded in 2016 and led by a physician-scientist, Aqualung's rigorous science-driven approaches led them to the identification of nicotinamide phosphoribosyltransferase (NAMPT) and other key proteins expressed in both acute and chronic inflammatory diseases. Aqualung Therapeutics is developing eNamptor™, a Next Gen platform comprised of: i) humanized eNAMPT-neutralizing monoclonal antibodies- ALT-100; ii) eNAMPT-Plex-a plasma-based biomarker panel comprised of cytokines including eNAMPT, which predicts ARDS mortality; and iii) NAMPT-Gene, a genotyping assay that identifies individuals with NAMPT genetic variants at increased risk for ARDS mortality. The Aqualung pipeline is designed to target a range of serious inflammatory diseases, including ARDS, ventilator- and radiation-induced lung injury, prostate cancer, pulmonary hypertension, pulmonary fibrosis, cardiac ischemia, non-alcoholic steatohepatitis or NASH and chorioamnionitis or intrauterine infection. These conditions all exhibit a significant unmet medical need with significant morbidity and mortality. For additional information about the company, please visit www.aqualungtherapeutics.com.

Aqualung Therapeutics Corporation

Tel: +1 (312) 618-7337
Joe GN "Skip" Garcia, MD, CEO & Founder
skip@aqualungtherapeutics.com

SOURCE: Aqualung Therapeutics Corporation 

ReleaseID: 591523

ENGlobal Announces $8.3 Million in New Business

HOUSTON, TX / ACCESSWIRE / May 27, 2020 / ENGlobal (NASDAQ:ENG), a leading provider of engineered modular solutions, today announced it had secured $8.3 million in new business thus far in the second quarter of this year, which represents new purchase orders plus additional scope on existing agreements. Highlights of the significant new work includes:

Additional scope of work valued at $2.8 million on a Midwestern U.S. renewable diesel facility;

A signed extension worth $2.1 million for analytical equipment and support services at a major refinery;

Two purchase orders totaling $900 thousand to design and supply analytical buildings for a Louisiana petrochemical plant; and

A subsea controls contract valued at $500 thousand for technical support services on ENGlobal's proprietary UMCS (Universal Master Control Station).

Revenue from the above projects is expected to be recognized over the course of this year.

"Given the current economic environment, we are pleased to announce this group of diverse projects and scope of work extensions," said CEO William Coskey, P.E. "We continue to pursue much larger modular automation systems and process plant awards that would significantly add to our backlog. These opportunities and proposals are in various stages of development, and we expect to provide further information as the year progresses."

About ENGlobal

ENGlobal (Nasdaq:ENG) is a provider of engineering and automation services primarily to the energy sector throughout the United States and internationally. ENGlobal operates through two business segments: Automation and Engineering. ENGlobal's Automation segment provides services related to the design, fabrication and implementation of distributed control, instrumentation and process analytical systems. The Engineering segment provides consulting services for the development, management and execution of projects requiring professional engineering, construction management, and related support services. Within ENGlobal's Engineering segment, ENGlobal Government Services, Inc. provides engineering, design, installation, operations, and maintenance of various government, public sector, and international facilities, specializing in turnkey automation and instrumentation systems for the U.S. Defense industry worldwide. Further information about the Company and its businesses is available at www.ENGlobal.com.

Safe Harbor for Forward-Looking Statements

The statements above regarding the Company's expectations, its operations and certain other matters discussed in this press release may constitute forward-looking statements within the meaning of the federal securities laws and are subject to risks and uncertainties For a discussion of risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ENGlobal's filings with the Securities and Exchange Commission, including the Company's most recent reports on Form 10-K and 10-Q, and other SEC filings.

Click here to join our email list: http://www.b2i.us/irpass.asp?BzID=702&to=ea&s=0.

CONTACT:

Mark A. Hess
Phone: (281) 878-1000
E-mail: ir@ENGlobal.com

Market Makers – Investor Relations
Jimmy Caplan
512-329-9505
Email: jimmycaplan@me.com

Market Makers – Media Relations
Rick Eisenberg
212-496-6828
Email: eiscom@msn.com

SOURCE: ENGlobal Corporation

ReleaseID: 591471

Assessing the COVID-19 Effect: Edible Fungus Production Moderately Disrupted by Labor Shortages of Labor in Pandemic, Says Future Market Insights Report

Leading edible fungus producers in market are seeking direct profits in retail sector to mitigate losses associated with wholesalers during the pandemic.

DUBLIN, IRELAND / ACCESSWIRE / May 27, 2020 / Rich nutrition profile of edible fungus has been garnering the interest of processed food sector. The advent of mushroom cultivation techniques also significantly drives revenue generation in edible fungus market. As projected by a new Future Market Insights (FMI) study, sales of edible fungus are set to cross the billion-dollar mark towards the end of 2030, but is currently witnessing heavy disruptions in supply chain due to COVID-19 pandemic. The problem is further being compounded by demand deceleration. Safeguarding the workforce amidst lockdown measures is a key strategy of edible fungus producers, aiming to sustain operations in the industry. The demand will recover steadily once the pandemic subsides, says the FMI study.

"During the COVID-19 crisis, the edible fungus industry has been pushing to comply with public health guidelines for social distancing, hygiene, and protective equipment for their workforce. On-farm guidance from the CDC, OSHA, and FDA, are influencing producers to set up protocols compliant with regulations from state and local public health and agriculture officials," says the FMI analyst.

Request report sample with 250+ pages to gain in-depth market insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-11580

Edible Fungus Market – Key Takeaways

Fresh mushrooms are anticipated to witness a strong growth in demand particularly in developed economies driven by demand for preservative-free, healthy foods.
The auricularia auricula-judae, and shitake species of edible fungus will rise substantially on account of demand for exotic cuisine.
Nutraceutical applications of edible fungus is likely to gain traction with rising consumer awareness about the health benefits associated with the product.
Asia Pacific will remain a leading regional market, with China as the largest producer and substantial increases in imports and exports in India and Japan, which boost the market in the region.

Edible Fungus Market – Key Driving Factors

Positive sales scenario, and a wide range of mushroom species are key factors contributing to market growth.
Rising demand for better nutrition and balanced diet programs in developing countries will generate remunerative opportunities.
Vegans and vegetarian consumers seeking alternative nutritive foods are choosing to consume mushrooms, for similar taste providing major impetus to market growth.
Rising investments in research & development to improve commercial cultivation of edible fungi also contribute to market growth.

Edible Fungus Market – Key Constraints

The potential side effects of skin allergies, stomach problems, and fatigue from consumption of edible fungus is expected to hinder market growth.
Limited production and distribution infrastructure for edible fungi in developing economies, is expected to impact the market.

The Anticipated Impact of Coronavirus

As the covid-19 virus continues to wreak havoc, exports of edible fungi out of China have been impacted, as governments around the world have been forced to enforce extended lockdowns. The current restrictions have upended international supply chains. As consumers are increasingly cautious of food safety, the market is witnessing a slowdown in demand. Also, the market is witnessing a notable shortage of labor for production activities, forcing companies to enforce measures to worker safety with minimal contact. Wholesaler sales have also taken a hit. Consequently, producers are seeking to offset such losses through collaborations with retailers.

Explore the global edible fungus market report with 88 illustrative figures, 96 data tables and the table of contents. You can also find a comprehensive market segmentation on https://www.futuremarketinsights.com/askus/rep-gb-11580

Competition Landscape

The edible fungus market is largely fragmented. Key players in the edible fungus market are Banken Champignons B.V., Agro Dutch Industries Ltd., BioFungi GmbH, Nasza Chata, California Mushroom Farms Inc., Scleta Mushrooms BV, Monaghan Mushrooms, and Highline Mushrooms. Majority of these players are seeking to increase cultivation capacity, which will remain a major growth driver. Companies are also investing in strategic collaborations, mergers and acquisitions to broaden regional presence.

More About the Report

The FMI's market research report of 300 pages offers comprehensive insights on edible fungus market. The market is analyzed on the basis of product type (shiitake, auricularia auricula-judae, pleurotus ostreatus, enokitake, agaricus bisporus, and others), and application (fresh mushrooms, dried mushrooms, canned mushrooms, frozen mushrooms, and others), across seven key regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).

Explore Extensive Coverage of FMI's Food & Beverages Landscape

Animal Feed Additives Market: Find detailed insights on the global animal feed additives market with segment-wide analysis, market statistics, influencing factors, prominent players and developmental strategies adopted by market players for a 10-year forecast period.

Cheese Powder Market: FMI's report on the global cheese powder market offers commentary on the market poised for prolific growth during 2020-2030. The study covers evaluation of impacting forces, revenue sources, market leaders and market strategies.

Spirulina Powder Market: Get a deep-dive analysis on the spirulina powder market with essential insights on growth levers, opportunities, restraints, regulatory policies, regional market forecast and key forte of market leaders.

About FMI

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FMI helps clients from across the globe with their unique business intelligence requirements. With a repository of over thousand reports and 1 million+ data points, the team has scrutinized the food & beverages sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.

Contact

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com

Market Report: https://www.futuremarketinsights.com/reports/edible-fungus-market
Press Release Source: https://www.futuremarketinsights.com/press-release/edible-fungus-market

SOURCE: Future Market Insights

ReleaseID: 591597

LAWSUITS FILED AGAINST SERV, IQ and HALL – JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

NEW YORK, NY / ACCESSWIRE / May 27, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Servicemaster Global Holdings, Inc. (NYSE:SERV)

CONTACT JAKUBOWITZ ABOUT SERV:
https://claimyourloss.com/securities/servicemaster-global-holdings-inc-loss-submission-form/?id=6911&from=1

Class Period : February 26, 2019 – November 4, 2019

Lead Plaintiff Deadline : June 9, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) ServiceMaster had failed to properly inspect and treat for Formosan termite activity; (b) as a result thereof, the Company was and continued to experience a material adverse trend of costly litigation from injured customers which was not disclosed to investors; (c) in an unsuccessful attempt to mitigate this trend, Defendants had been taking remedial measures since at least 2018, including drastically raising prices for termite treatments in Mobile, Alabama to deter contract renewals; and (d) as a result of the foregoing, ServiceMaster's financial results were reasonably likely to be impacted, and would continue to impact the Company into 2020.

iQIYI, Inc. (NASDAQ:IQ)

CONTACT JAKUBOWITZ ABOUT IQ:
https://claimyourloss.com/securities/iqiyi-inc-loss-submission-form/?id=6911&from=1

The IQ lawsuit is on behalf of persons and entities other than Defendants that purchased or otherwise acquired: (a) iQIYI American Depository Shares pursuant and/or traceable to the Company's initial public offering conducted on or about March 29, 2018; or (b) iQIYI securities between March 29, 2018, and April 7, 2020.

Lead Plaintiff Deadline : June 15, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) iQIYI inflated its revenue figures; (2) iQIYI inflated its user numbers; (3) iQIYI inflated its expenses to cover up other fraud; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Hallmark Financial Services, Inc. (NASDAQ:HALL)

CONTACT JAKUBOWITZ ABOUT HALL:
https://claimyourloss.com/securities/hallmark-financial-services-inc-loss-submission-form/?id=6911&from=1

Class Period : March 5, 2019 – March 17, 2020

Lead Plaintiff Deadline : July 6, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective internal controls over accounting and financial reporting related to reserves for unpaid losses; (2) the Company improperly accounted for reserve for unpaid losses and loss adjustment expenses related to its Binding Primary Commercial Auto business; (3) as a result, Hallmark Financial would be forced to report a $63.8 million loss development for prior underwriting years; (4) as a result, Hallmark Financial would exit from its Binding Primary Commercial Auto business; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

ReleaseID: 591602

Lucky Minerals Announces the Appointment of New Board Members and Strategic Advisors

VANCOUVER, BC / ACCESSWIRE / May 27, 2020 / Lucky Minerals Inc. (TSXV:LKY)(OTC PINK:LKMNF)(FRA:LKY) ("Lucky" or the "Company") is pleased to announce the appointment of two new independent board members to further enhance the team. The new appointees include Mr. Blake Hylands and Mr. Paul Pint as directors of the Company. Lucky is also pleased to announce that Dr. Alan Wilson and Mr. Justin Reid will join the Company in an advisory capacity.

Collectively, this is a highly experienced technical and capital markets team and is responsible for the recent discovery of over 4.5Moz of gold and raising of over $65 million in their capacity as founders and management of Troilus Gold. Additionally, Dr. Alan Wilson has worked extensively with Antofagasta Minerals and Anglo American plc on international exploration programs, focused on world-class copper deposits. His experience in South America will be a valuable asset to Lucky as it works with First Quantum on the Fortuna project. Lucky Minerals is focused on building an experienced team with knowledge and a proven track-record of advancing assets from discovery through the entire value creation cycle.

Additionally, Mr Joao Carrelo has resigned from the Board, effective immediately, and Mr Francois Perron has been appointed Chairman of the Board. The new directorships take effect immediately and will work with our existing team as the Company advances the Fortuna exploration project. The Company and its Board thank Mr. Carrelo for his contributions to the team and wish him well in his future endeavours.

Adrian Rothwell, President and CEO stated: "We are extremely pleased to be adding this expertise to our team. The new members have broad expertise in all aspects of the mining and financial industry and come with a proven track record of exploration, and developing, financing and operating mining projects. This is a major step to reset Lucky Minerals as an active company with a new team and to quickly advance our Fortuna gold and copper project."

Joao Carrelo stated "Since acquiring the Ecuador assets we have been able to identify a strong strategic partner to explore our copper potential and have built an in-house team to focus on our gold targets. Over the last year we appointed strong management leadership in Adrian Rothwell, and with today's board additions of Paul Pint and Blake Hylands under the chairmanship of Francois Perron, we established a Board with the skill sets and the collective experience that will meet the current and future needs of the company. I am leaving the company in good hands and convey my best wishes to all Lucky stakeholders."

Brief biographies of the directors and advisors are highlighted below.

Paul Pint, CPA, CA – Board Member: Mr. Pint is a capital markets professional with over 25 years of experience. Mr. Pint began his capital markets career on the Institutional Equity team at CIBC World Markets, where he held various senior positions and was instrumental in building and developing their Private Placements and Small Cap Equity group. Over his career, he has held a number of senior positions at various financial institutions and boutique investment banks in Canada. Mr. Pint has been involved in over 500 financings for companies in North America and globally. Mr. Pint is the current President of Troilus Gold Corporation. Mr. Pint is a Chartered Professional Accountant and holds a Bachelor of Commerce degree from the University of Toronto.

Blake Hylands, P.Geo. – Board Member:

Mr. Hylands has spent a majority of his career working in gold, base metals and iron ore exploration in Canada and internationally. He has managed a number of multi-million dollar, large-scale, global exploration programs. Over the last three years he has driven one of the largest concentrated exploration programs in Canada whereby redefining the Troilus Gold Deposit into one of Canada's largest developing resources. Mr. Hylands holds a B.Sc in Geology from Western University in London, Ontario and currently serves as an Officer of Troilus Gold, with the roles of Senior Vice-President of Exploration and Corporate Development.

Alan Wilson, Ph.D. – Advisor: Dr. Wilson is an experienced economic geologist with significant track record in exploration for and evaluation of base and precious metal prospects and deposits globally. Alan has near three decades of exploration experience throughout South and North America, Central and Southern Africa, Australasia and Europe with a demonstrated focus on practical field geology and due diligence for all stages of resource projects. Most recently, as the International Exploration Manager for Antofagasta Minerals (2010 to 2019), Alan was responsible for the development and execution of its global exploration program outside of Chile, including technical evaluation of opportunities, negotiation of commercial agreements, and ensuring safe and cost-effective evaluation of exploration targets. From 2006 to 2010, Alan was the Copper Commodity Leader for Anglo American, where he was tasked with ensuring technical excellence at all copper exploration projects globally and with oversight on copper exploration R&D projects and new initiatives. Alan has a PhD in Economic Geology from the University of Tasmania, a MSc in Exploration and Mining Geology from the University of Leicester and BSc (Honours) in Geology from the University of Edinburgh.

Justin Reid, M.Sc., MBA – Advisor: Mr. Reid is the founder and Chief Executive Officer of Troilus Gold Corporation, launched in January 2017. He is a geologist and capital markets executive with over 20 years of experience focused exclusively in the mineral resource space. Mr. Reid started his career as a geologist with Saskatchewan Geological Survey and Cominco Global Exploration after which he became a partner and senior mining analyst at Sprott/Cormark Securities in Toronto. He was then named Executive General Manager at Paladin Energy, where he was responsible for leading all merger and acquisition, corporate and market related activities. He is the former Managing Director Global Mining Sales at National Bank Financial, where he directed the firm's sales and trading in the mining sector. Most recently, he acted as President and Director of Sulliden Gold Corporation, until its acquisition by Rio Alto Mining. Mr. Reid is the Chief Executive Officer and Founder of Troilus Gold Corp. He holds a B.Sc (Geology) from the University of Regina, a M.Sc (Geology) from the University of Toronto and an MBA from the Kellogg School of Management at Northwestern University.

The Company's Technical Committee consists of Mr. Victor Jaramillo (also the Company's Exploration Manager), Dr. Alan Wilson, and members of the Board of Directors, Mr. Shaun Dykes and Mr Blake Hylands.

More information on the Company's Technical Committee can be found at luckyminerals.com.

Financing Update

On May 15, 2020, the Company announced a non-brokered private placement of up to $3,500,000 (the "Offering"), led by Palisades Goldcorp Ltd. and a concurrent consolidation of its share capital on the basis of one (1) new share for each seven and one-half (7.5) shares currently outstanding. Conditional approval from the TSX Venture Exchange has been received and the Offering may close in multiple tranches.

About Lucky

Lucky is an exploration and development company targeting large-scale mineral systems in proven districts with the potential to host world class deposits. Lucky owns a 100% interest in the Fortuna and Emigrant Creek Projects.

The Company's Fortuna Project is a royalty-free 550km2 (55,000 Ha, or 136,000 Acres) exploration concession located in a highly prospective, yet underexplored, gold belt in southern Ecuador. Lucky has entered into a Memorandum of Understanding on Fortuna with First Quantum Minerals Ltd. ("First Quantum") whereby First Quantum is able to earn up to 70% on primary copper targets.

Lucky's Fortuna is a large project, with multiple known copper-molybdenum-gold porphyry and high sulfidation epithermal gold targets located throughout the twelve concessions.

The Emigrant Creek Project covers a 15 km2 area in an intensely altered and mineralized porphyry copper-gold-molybdenum system in southern Montana.

ON BEHALF OF THE BOARD

"Adrian Rothwell"

Chief Executive Officer

Further information on Lucky can be found on the Company's website at www.luckyminerals.com and at www.sedar.com, or by contacting Adrian Rothwell, President and CEO, by email at investors@luckyminerals.com or by telephone at (866) 924 6484.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Adjacent Properties and Forward-Looking Information

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Such factors include, but are not limited to: uncertainties related exploration and development; the ability to raise sufficient capital to fund exploration and development; changes in economic conditions or financial markets; increases in input costs; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; technological or operational difficulties or inability to obtain permits encountered in connection with exploration activities; and labor relations matters. This list is not exhaustive of the factors that may affect the Company's forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations also include risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

SOURCE: Lucky Minerals Inc.

ReleaseID: 591574

CANEX Initiates Field Program at Gold Range, Arizona

CALGARY, AB / ACCESSWIRE / May 27, 2020 / CANEX Metals Inc. (TSXV:CANX) ("CANEX" or the "Company") is pleased to announce that a soil sampling program is underway at the Gold Range Property, Arizona.

A local contractor is currently conducting a 777 sample soil program at Gold Range which is expected to take about 7 days to complete. The sampling program will follow up and expand on multiple new gold-in-soil anomalies identified in the southern part of the claim block and expand coverage around 2 new high grade gold in outcrop discoveries (previously announced see May 11, 2020 news release). A summary map showing gold in soil anomalies and the 2 new gold discoveries from the southern part of the claim block is available here.

Additional sampling will be conducted at the Central Zone gold-in-soil anomaly which is currently 730 metres long by up to 250 metres wide and open to the north, a map of the Central Zone gold-in-soil anomaly is available here. Grid soil sampling is also planned around the Tin and Shaft Zones to help assess their strike potential, and several reconnaissance soil lines will be conducted in the northern part of the claim block over areas that have seen limited prior exploration.

The Company will continue to advance Gold Range in preparation for drill testing as travel and other restrictions allow.

About the Gold Range Property

The Gold Range Property is located in Northern Arizona within an area that has seen historic lode and placer gold production but limited systematic modern lode gold exploration. Fieldwork by the Company has identified numerous gold exploration targets on the property with grab samples from outcropping quartz veins returning multiple values in the 20 to 40 g/t gold range, and chip sampling returning values of 53.2 g/t gold over 0.6 metres, 31.7 g/t gold over 1 metre, 24.3 g/t gold over 1.5 metres, 28.1 g/t gold over 1 metre, 17.2 g/t over 1.1 metre, and 8.47 g/t gold over 5.6 metres. Please visit our website at www.canexmetals.ca for additionnel information.

Dr. Shane Ebert P.Geo., is the Qualified Person for CANEX Metals and has approved the technical disclosure contained in this news release.

"Shane Ebert",

Shane Ebert
President/Director

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Except for the historical and present factual information contained herein, the matters set forth in this news release, including words such as "expects", "projects", "plans", "anticipates" and similar expressions, are forward-looking information that represents management of CANEX Metals Inc. internal projections, expectations or beliefs concerning, among other things, future operating results and various components thereof or the economic performance of CANEX. The projections, estimates and beliefs contained in such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause CANEX's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, those described in CANEX's filings with the Canadian securities authorities. Accordingly, holders of CANEX shares and potential investors are cautioned that events or circumstances could cause results to differ materially from those predicted. CANEX disclaims any responsibility to update these forward-looking statements.

For Further Information Contact:

Shane Ebert at 1.250.964.2699 or
Jean Pierre Jutras at 1.403.233.2636
Web: http://www.canexmetals.ca

SOURCE: CANEX Metals Inc.

ReleaseID: 591491

GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial

FIRST PATIENT ACHIEVED STABLE DISEASE WITH NO ADVERSE SIDE EFFECTS

LOS ANGELES, CA / ACCESSWIRE / May 27, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on NK cell engager (TriKE™) technology. GT announced today that the second patient of the lowest dose of an ascending dose finding study has begun treatment of the GTB-3550 TriKE™. The patient will be evaluated following completion of the third cycle of GTB-3550 TriKE™ therapy. The clinical trial is being conducted at the University of Minnesota's Masonic Cancer Center in Minneapolis. Additional clinical trial sites are now being processed.

The first patient of the Phase I/II study achieved stable disease and increased NK cell production with no adverse side effects. The first patient elicited an encouraging initial efficacy marker response.

The TRIKE™ clinical trial evaluates GTB-3550 in patients with acute myeloid leukemia or advanced systemic mastocytosis, and will determine safety and tolerability as well as the pharmacologically active dose and maximum tolerated dose of GTB-3550.

TriKE™ is a multi-targeted immuno-oncology protein-based therapeutic drug. The TriKE™ addresses the patient delivery and administration issues of liquid tumor cell therapies and NK engagers. Pre-clinical data shows that The TriKE™ platform technology works in both liquid and solid tumors.

About GTB-3550 Trispecific NK cell Engager (TriKE™)

GTB-3550 is the Company's first TriKE™ product candidate being initially developed for the treatment AML. GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The natural killer (NK) cell stimulating cytokine human IL-15 portion of the molecule provides a self-sustaining signal that activates NK cells and enhances their ability to kill. The Company is currently in a clinical trial with GTB-3550 in CD33 positive leukemia for acute myeloid leukemia (AML), and is studying myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies along with other solid tumor candidates.

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary Tri-specific Killer Engager (TriKE™) platform. The TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize cancer therapies using proprietary TriKE technology developed by researchers at the university to target NK cells to cancer.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Form 10-K for the fiscal year ended December 31, 2019 in the section titled "Risk Factors" in Part I, Item 1A and in our subsequent filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.

Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials for GTB-3550 or GTB-1550, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

For more information, please visit www.gtbiopharma.com

Media Contact – 800-304-9888

SOURCE: GT Biopharma, Inc.

ReleaseID: 591565

New Jersey Mining Company Acquires Diamond Creek Rare Earth Element Deposit in Idaho

COEUR D'ALENE, ID / ACCESSWIRE / May 27, 2020 / New Jersey Mining Company (OTCQB:NJMC) ("NJMC" or the "Company") is pleased to announce the strategic expansion of its land holdings to include the Diamond Creek Rare Earth Element (REE) deposit in Lemhi County, Idaho.

The Diamond Creek REE Project covers approximately 421 hectares (1,040 acres) and is comprised of 52 unpatented mining claims. It is located in the Eureka Mining district, approximately 13 kilometers (8 miles) north-northwest of the town Salmon, Idaho.

The REE-bearing veins of the Diamond Creek area are on the short list of the well-recognized and studied occurrences in the United States. In 1979, M.H.Staatz, of the U.S. Geological Survey (USGS) estimated an overall probable resource at Diamond Creek of approximately 70,800 metric tonnes of total rare-earth oxides, using an average grade of 1.22 percent (Table 1). Reported sample assays show REE oxide contents ranging from 0.59 to 5.51 percent. Additionally, three samples cut across one of the larger veins were assayed for gold, and contained 0.5, 2.4 and 11.9 grams per tonne (0.017, 0.07, and 0.348 ounces per ton).

NJMC VP of Exploration, Rob Morgan commented, "It is very rare to acquire a mineral property of this quality, especially one with a published potential resource originally outlined by the USGS and officially recognized as part of our national inventory of critical mineral occurrences. We strongly feel this property package holds potential well beyond the historic resource estimate and look forward to building upon the quality work completed by the folks at the USGS, Idaho Geological Survey and other companies."

The REE mineralization at Diamond Creek is found in quartz veins over a large area approximately 3.2 km (2 mi) long and 0.8 km (0.5 mi) wide. After careful geologic interpretation, extensive review of historic reports and on-site analysis by Company geologists, the claim block was aligned to include the historic resource outlined by the USGS as well as including most of the remaining REE vein system. The Diamond Creek area was held almost continuously from the 1960's until 2015 when REE prices plunged – allegedly due to China's market manipulation as the world's leading REE supplier – and domestic short-term money and political energy focused elsewhere.

The area was historically prospected for gold until 1949 when its unique geologic setting was recognized by the USGS and the Idaho Geological Survey. In the early 1950's the U.S. government-sponsored country-wide exploration for nuclear power-related raw materials. This campaign resulted in the discovery of thorium in areas of Lemhi County, including the REE occurrence in the Diamond Creek area. The exploration efforts of the USGS and other agencies resulted in the inclusion of Diamond Creek into our country's recognized critical minerals inventory. To further its efforts toward identifying domestic sources of critical minerals, the USGS has been conducting comprehensive mapping and LIDAR coverage of many areas, including the Diamond Creek area (and other areas of Idaho). Our appreciation of these services cannot be understated.

Mr. Morgan further commented, "At Diamond Creek we are building upon a valuable base of information, including the association of gold and REE minerals together. At Diamond Creek, the gold and REE's occur within the same veins, but it is not clear if the gold is genetically related to the REE mineralization. Some of the mineral pulses have gold, thorium, uranium, niobium, yttrium and REE's. Niobium and gold are possible by-products that would add greatly to the economics of the recognized deposits in Diamond Creek.

The geologic setting at Diamond Creek developed over millions of years of unusual structural dynamics. REE's are volatiles, originating from differentiating deep igneous bodies that travel along deep-seated structures to the surface. Some of these structures are present in the Diamond Creek area and manifest themselves as veins hosted in billion-year-old, metamorphosed quartzites and granites. There are at least eight known veins and they range in width from 0.15 to 7.6 m (0.5 to 25 ft) in thickness. Vein widths appear best developed in the metasediments and can be traced on the surface for distances ranging from 33.5 to 780 m (110 to 2,560 ft). Down-dip extensions of these mineralized veins have never been sufficiently tested. Historical reports indicate two short core holes have been completed with some significant mineralization noted.

NJMC President and CEO John Swallow stated, "As we have discussed before; jurisdiction and location are everything if a project is going to retain a base of value. The global reactions to the events of the last few months demonstrated, with clarity, that the long-dormant ‘defensive readiness/low-carbon future' playbook was ready to pull down from the NJMC shelf. Fortunately, the presentation of this opportunity occurred after having achieved commercial gold production and consolidating a long-overlooked gold district. Furthermore, the breadth of our overall business experience in this industry, as well as the technology and the DoD sectors, tells us that the time for public/private partnerships with regard to strategic mineral use in future technologies, national stockpiles and mineral processing/milling is (finally) here. We look forward to applying our business, exploration, milling and mining expertise to a defined REE subset within the critical minerals sector."

Table 1: Domestic reserves and resources of rare earth elements, excluding heavy-mineral placer and phosphate deposits.

Long, K.R., Van Gosen, B.S., Foley, N.K., and Cordier, Daniel, 2010, The principal rare earth elements deposits of the United States-A summary of domestic deposits and a global perspective: U.S. Geological Survey Scientific

Investigations Report 2010-5220, 96 p., accessed March 13,2019, at https://pubs.er.usgs.gov/publication/sir20105220.

Qualified person

NJMC's Vice President of Exploration, Robert John Morgan, PG, PLS is a qualified person as such term is defined in National Instrument 43-101 and has reviewed and approved the technical information and data included in this press release.

About New Jersey Mining Company

Headquartered in North Idaho, New Jersey Mining Company is the rare example of a vertically integrated operating junior mining company. NJMC produces gold at the Golden Chest Mine and recently consolidated the Murray Gold Belt (MGB) for the first time in over 100-years. The MGB is an overlooked gold producing region within the Coeur d'Alene Mining District, located north of the prolific Silver Valley. In addition to gold, the Company maintains a presence in the Critical Minerals sector and is focused on identifying and exploring for Critical Minerals (Rare Earth Minerals) important to our country's defensive readiness and a low-carbon future.

New Jersey Mining Company possesses the in-house skillsets of a much larger company while enjoying the flexibility of a smaller and more entrepreneurial corporate structure. Its production-based strategy, by design, provides the flexibility to advance the Murray Gold Belt and/or its Critical Minerals holdings on its own or with a strategic partner in a manner that is consistent with its existing philosophy and culture. NJMC has established a high-quality, early to advanced-stage asset base in four historic mining districts of Idaho and Montana, which includes the currently producing Golden Chest Mine. Management is stakeholder focused and owns more than 15-percent of NJMC stock.

The Company's common stock trades on the OTC-QB under the symbol "NJMC."

For more information on New Jersey Mining Company go to www.newjerseymining.com or call:

Monique Hayes
Corporate Secretary/Investor Relations
Email: monique@newjerseymining.com
(208) 625-9001

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be covered by the safe harbor created by such sections. Such statements are based on good faith assumptions that New Jersey Mining Company believes are reasonable, but which are subject to a wide range of uncertainties and business risks that could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Such factors include, financial and operating results and estimates, future resource estimates, future business goals, competitive strengths, project development, or the Company's ability to identify Critical Minerals and or Rare Earth Element demonstrating technical and economic viability, the risks and hazards inherent in the mining business (including risks inherent in developing mining projects, environmental hazards, industrial accidents, weather or geologically related conditions), changes in the market prices of gold and silver and the potential impact on revenues from changes in the market price of gold and cash costs, a sustained lower price environment, as well as other uncertainties and risk factors. Actual results, developments and timetables could vary significantly from the estimates presented. Readers are cautioned not to put undue reliance on forward-looking statements. NJMC disclaims any intent or obligation to update publicly such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: New Jersey Mining Company

ReleaseID: 591550

Ideal Power to Present at the June 2020 Virtual Investor Summit

AUSTIN, TX / ACCESSWIRE / May 27, 2020 / Ideal Power Inc. (NASDAQ:IPWR) ("Ideal Power" or the "Company" ), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN™ bi-directional power switches, today announced that management will present at the June 2020 Virtual Investor Summit on June 9-12, 2020.

Dan Brdar, President and Chief Executive Officer, and Tim Burns, Chief Financial Officer, will host virtual one-on-one investor meetings throughout the event and the Company is scheduled to present as follows:

Virtual Investor Summit
Date: Tuesday, June 9, 2020
Time: 1:35 p.m. Eastern time (10:35 a.m. Pacific time)
Webcast: https://www.webcaster4.com/Webcast/Page/2038/35031

Conference participation is by invitation only and registration is mandatory. For more information, or to schedule a virtual one-on-one meeting, please contact your conference representative.

About Ideal Power Inc.
Ideal Power (NASDAQ:IPWR) is pioneering the development of its broadly patented bi-directional power switches, creating highly efficient and ecofriendly energy control solutions for industrial, alternative energy, military and automotive applications. The Company is focused on its patented Bi-directional, Bi-polar Junction Transistor (B-TRAN™) semiconductor technology. B-TRAN™ is a unique double-sided bi-directional AC switch able to deliver substantial performance improvements over today's conventional power semiconductors. Ideal Power believes B-TRAN™ modules will reduce conduction and switching losses, complexity of thermal management and operating cost in medium voltage AC power switching and control circuitry. For more information, visit www.IdealPower.com.

Ideal Power Investor Relations Contact:
MZ North America
Chris Tyson
949-491-8235
IPWR@mzgroup.us
www.mzgroup.us

SOURCE: Ideal Power Inc.

ReleaseID: 591445